Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Jun
25
Today In Oncology
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
Multi-Cancer Early Detection Test Performs Well in Real-World Asian Cohort
Subgroup Analysis Demonstrates Efficacy of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
Chinese Study of HER2-Targeted Combination Therapy for Locally Advanced Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo